← Back to front page
United States · Wires & real time · PR Newswire

Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer

Published by PR Newswire · United States 29 min ago

Detailed summary

The opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is Innovent's first European regulatory milestone; if approved,…

PALO ALTO, Calif. and SUZHOU, China, Nov. 15, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces it has received its first positive opinion from the CHMP of the European Medicines Agency (EMA). The CHMP recommends marketing authorization of Zybrivo® (sintilimab), in combination with chemotherapy, for adults with advanced non-squamous non-small cell lung cancer (NSCLC).

"At Innovent, our mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals. The positive CHMP opinion for Zybrivo marks an important regulatory milestone in our international development and brings us a step closer to serving patients in Europe." said Dr. Hui Zhou, Chief R&D Officer of Oncology at Innovent. "Zybrivo has demonstrated clear clinical benefits in the ORIENT-11 study and, if approved, could provide an additional treatment option for patients in Europe with non-squamous non-small cell lung cancer. Building on this progress, we will continue advancing our innovative pipeline and working to bring meaningful medicines to patients around the world."

Following the CHMP's positive opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the authorization will be valid across all 27 European Union (EU) member states, as well as Iceland, Norway, and Liechtenstein.

Sintilimab, as an immunotherapy, is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).

The CHMP recommendation is based on results of ORIENT-11, a randomized, multicenter, double-blind, placebo-controlled Phase 3 study that enrolled 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC with…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading